Blog
RSS FeedPosted by Michael Wonder on 12 Nov 2019
Labour peer says he opposes Corbyn-style state-funded drugs firm
12 November 2019 - A Labour peer has spoken out against the idea of a nationalised drugs industry, saying that ...
Posted by Michael Wonder on 07 Nov 2019
The FDA needs to set standards for using artificial intelligence in drug development
7 November 2019 - Artificial intelligence has become a crucial part of our technological infrastructure and the brain underlying many ...
Posted by Michael Wonder on 15 Oct 2019
Wanted: better policies and incentives to revitalise R&D for new antimicrobial drugs
15 October 2019 - In the not-too-distant future that we could be facing — one with rampant, uncontrollable, multidrug-resistant microbes ...
Posted by Michael Wonder on 10 Oct 2019
FDA cuts red tape in diagnosis applications for cancer trials
10 October 2019 - Drug companies developing cancer treatments can fold the risk assessment of unapproved screening tests into their ...
Posted by Michael Wonder on 08 Oct 2019
FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
8 October 2019 - The U.S. FDA today announced that it has awarded 12 new clinical trial research grants totaling ...
Posted by Michael Wonder on 02 Oct 2019
The real impact of drug price legislation on biopharmaceutical R&D
2 October 2019 - As outcry around drug prices rages, arguments continue to surface that limiting corporate revenues via price controls ...
Posted by Michael Wonder on 01 Oct 2019
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
1 October 2019 - Multi-year alliance underpins the Novartis commitment to leverage data & artificial intelligence to transform how medicines are ...
Posted by Michael Wonder on 30 Sep 2019
AI needs patients’ voices in order to revolutionise health care
30 September 2019 - Patients’ stories — what doctors call patient histories — are the bedrock of medicine. “Listen to ...
Posted by Michael Wonder on 30 Sep 2019
FDA issues draft guidance on patient-focused drug development: methods to identify what is important to patients
30 September 2019 - Today the U.S. FDA issued a draft guidance on Patient-Focused Drug Development: Methods to Identify What Is ...
Posted by Michael Wonder on 22 Sep 2019
Interacting with the FDA on complex innovative trial designs for drugs and biological products
20 September 2019 - This document provides guidance to sponsors and applicants on interacting with the FDA on complex innovative trial ...
Posted by Michael Wonder on 16 Sep 2019
FDA seeks input on product-specific guidances to facilitate generic drug development
16 September 2019 - Today, FDA published 53 product-specific guidances (PSGs) – 34 new guidances and 19 revised guidances, including ...
Posted by Michael Wonder on 09 Sep 2019
Subscription model for antibiotic development
6 September 2019 - An unlikely answer to the global crisis in antibiotic resistance. ...
Posted by Michael Wonder on 09 Sep 2019
Who’s missing from breast cancer trials? Men, says the FDA
9 September 2019 - Men do get breast cancer, but they account for fewer than 1 percent of patients and often ...
Posted by Michael Wonder on 28 Aug 2019
Promoting paediatric drug research and labelling — outcomes of legislation
28 August 2019 - Congress has modified regulations of the FDA to promote research assessing the efficacy and safety of drugs ...
Posted by Michael Wonder on 28 Aug 2019
FDA urges inclusion of men in breast cancer clinical trials
28 August 2019 - Men with breast cancer make up less than one percent of all breast cancer cases, but ...